Hirsutism Clinical Trial
Official title:
Clinical Evaluation of Silk'n Glide for Face
NCT number | NCT02103608 |
Other study ID # | DO105306A |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | September 2013 |
Est. completion date | December 2014 |
Verified date | September 2016 |
Source | Home Skinovations Ltd. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a clinical study to determine the efficacy and safety of the Glide, hair removal photo-depilation device, for removing facial hairs. During the first stage, the subjects will perform up to 6 face treatments, two weeks apart. The treatment's safety and efficiency will be evaluated at 4 weeks of after last treatment and at 12 weeks after last treatment.
Status | Completed |
Enrollment | 17 |
Est. completion date | December 2014 |
Est. primary completion date | July 2014 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 21 Years to 60 Years |
Eligibility |
Inclusion Criteria: 1. Presence of unwanted hairs on the face 2. Skin Type I to IV (Fitzpatrick) 3. Adults older than 21 years of age but not more than 60 years of age. 4. Must be either post-menopausal or surgically steri-lized, or using a medically acceptable form of birth control (i.e., oral contraceptives, IUD, contraceptive implant, barrier methods with spermicide or absti-nence). 5. Informed consent agreement by the subject. 6. Willingness to follow the treatment schedule and post treatment care. Exclusion Criteria: 1. Malignant or pre-malignant pigmented lesions in the area to be treated. 2. Scarring or infection of the area to be treated. 3. Known photosensitivity. 4. Pregnancy or lactating 5. Subjects with Diabetes (Type I or II). 6. Presence of a suntan in the area to be treated. 7. Use of medication known to induce photosensitivity. 8. Subject is on anticoagulative medication or throm-boembolic condition. 9. Subjects with a pacemaker or internal defibrillator. 10. Use of NSAIDS two weeks prior to, and two weeks following the treatment. 11. Subjects that use waxing or other methods of photo-epilation 3 months prior to treatment. 12. Subjects that have been exposed to strong sunlight or an artificial tanning machine during the past 4 weeks 13. Subjects wearing a tattoo or permanent makeup on the area to be treated 14. Subjects with dark brown or black spots, such as large freckles, birth marks, moles or warts on the area to be treated 15. Subjects with Eczema, psoriasis, lesions, open wounds or active infections, such as cold sores in the area to be treated 16. Subjects with history of keloidal scar formation 17. Subjects with history of herpes outbreaks in the area of treatment, unless you have consulted your physician and received preventative treatment before using GlideTM 18. Subjects with epilepsy 19. Subjects using incontinence device, insulin pump, other active devices [NB: Protocol excludes pace-makers and internal defibrillators.] 20. Subjects with a history of skin cancer or areas of po-tential skin malignancies 21. Subjects who have received radiation therapy or chemotherapy treatments within the past 3 months |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Home Skinovations Ltd. |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | 1. Comparison of Hair Counts Before Treatments to 4 and 12 Weeks Follow up Visits. | Hair count is going to be preformed and base line and compare with the count at 4 weeks and 12 weeks. % of hair reducation is going to be calculated. | 4 weeks and 12 weeks post treatment |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT00495443 -
Enhanced Safety Aesthetic Laser System
|
N/A | |
Not yet recruiting |
NCT06003062 -
Suppression of Upper Lip Hair Growth Using Novel Hemp Extract
|
||
Active, not recruiting |
NCT00145288 -
Prospective Study of Patients With Hirsutism
|
Phase 2/Phase 3 | |
Completed |
NCT00152048 -
Evaluation of Eflornithine on Facial and Forearm Skin
|
Phase 4 | |
Enrolling by invitation |
NCT01461694 -
Facial Hair Reduction Using Intense Pulsed Light (IPL) & Alexandrite Laser
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT00441948 -
Enhanced Safety Laser Hair Removal System
|
N/A | |
Completed |
NCT03673995 -
Myoinositol Plus L-tyrosine, Selenium and Chromium in PCOS
|
N/A | |
Recruiting |
NCT04979377 -
Prevalence of Hyperandrogenism in Type 1 Diabetes
|
||
Completed |
NCT02494297 -
DUS on the Prescribing Indications for CPA/EE in 5 European Countries
|
||
Completed |
NCT00960310 -
Relative Bioavailability Study of Bicalutamide 50 mg Tablet and Casodex Following a 50 mg Dose in Healthy Subjects Under Fed Conditions
|
Phase 1 | |
Completed |
NCT02793557 -
Investigation of FOL-005 on Clinical Safety and Effect on Hair Growth
|
Phase 1/Phase 2 | |
Completed |
NCT01817894 -
Treatment With Topical Eflornithin After Laser Treatment in Women With Facial Hirsutism
|
Phase 4 | |
Completed |
NCT01555190 -
Combination Therapy With Myo-inositol and Folic Acid Versus Myo-inositol Alone
|
N/A | |
Completed |
NCT00143052 -
Bone Status and Insulin Resistance in Hirsutism
|
N/A | |
Recruiting |
NCT01338519 -
Database Study on Patients With PCOS
|
N/A | |
Recruiting |
NCT04292587 -
Prevalence of Hirsutism in Turkey: Data of The Dermatoendocrinology Study Group
|
||
Completed |
NCT00959335 -
Relative Bioavailability Study of Bicalutamide 50 mg Tablet and Casodex Following a 50 mg Dose in Healthy Subjects Under Fasting Conditions
|
Phase 1 | |
Not yet recruiting |
NCT00371930 -
Photodynamic Therapy for Permanent Hair Removal
|
Phase 1/Phase 2 |